# SRAM (NCT03938649)

> SRAM study_Postate Cancer

No report yet. It can be ordered.

- Indication: high-risk prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03938649
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: CCTU
- Conditions: Advanced Prostate Cancer
- Interventions: Conventional IMRT; SBRT
- Enrollment: 120
- Primary outcome: To compare acute toxicities between SBRT and conventional IMRT

## Indexed commentary on SRAM so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sram-nct03938649
